logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 1
  • Stasi, Massimiliano
    Entrepreneur born in April 1960
    Individual (1 offspring)
    Officer
    icon of calendar 2022-07-19 ~ now
    OF - Director → CIF 0
    Massimiliano Stasi
    Born in April 1960
    Individual (1 offspring)
    Person with significant control
    icon of calendar 2016-04-06 ~ now
    PE - Ownership of shares – 75% or moreCIF 0
    PE - Ownership of voting rights - 75% or moreCIF 0
    PE - Right to appoint or remove directorsCIF 0
Ceased 2
  • 1
    Stasi, Alessio
    Quality Assurance Manager born in February 1968
    Individual
    Officer
    icon of calendar 2012-08-07 ~ 2022-07-19
    OF - Director → CIF 0
  • 2
    icon of address16, Old Bailey, London, United Kingdom
    Active Corporate (6 parents, 125 offsprings)
    Equity (Company account)
    2 GBP2024-06-30
    Officer
    2012-08-07 ~ 2016-04-01
    PE - Secretary → CIF 0
parent relation
Company in focus

INNOPHARMA INTERNATIONAL UK LIMITED

Standard Industrial Classification
82990 - Other Business Support Service Activities N.e.c.
Brief company account
Average Number of Employees
02024-01-01 ~ 2024-12-31
02023-01-01 ~ 2023-12-31
Par Value of Share
Class 1 ordinary share
12024-01-01 ~ 2024-12-31
Debtors
26 EUR2024-12-31
26 EUR2023-12-31
Cash at bank and in hand
151 EUR2024-12-31
155 EUR2023-12-31
Current Assets
177 EUR2024-12-31
181 EUR2023-12-31
Creditors
Current
4,715 EUR2024-12-31
4,535 EUR2023-12-31
Net Current Assets/Liabilities
-4,538 EUR2024-12-31
-4,354 EUR2023-12-31
Total Assets Less Current Liabilities
-4,538 EUR2024-12-31
-4,354 EUR2023-12-31
Equity
Called up share capital
500 EUR2024-12-31
500 EUR2023-12-31
Retained earnings (accumulated losses)
-5,038 EUR2024-12-31
-4,854 EUR2023-12-31
Equity
-4,538 EUR2024-12-31
-4,354 EUR2023-12-31
Property, Plant & Equipment - Gross Cost
Computers
1,334 EUR2023-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Computers
1,334 EUR2023-12-31
Amount of value-added tax that is recoverable
Current
26 EUR2024-12-31
26 EUR2023-12-31
Trade Creditors/Trade Payables
Current
155 EUR2024-12-31
Other Creditors
Current
3,960 EUR2024-12-31
3,960 EUR2023-12-31
Accrued Liabilities
Current
600 EUR2024-12-31
575 EUR2023-12-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
500 shares2024-12-31

  • INNOPHARMA INTERNATIONAL UK LIMITED
    Info
    Registered number 08171451
    icon of address3rd Floor 207 Regent Street, London W1B 3HH
    Private Limited Company incorporated on 2012-08-07 (13 years 2 months). The company status is Active.
    The last date of confirmation statement was made at 2024-06-24
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

The content of this website is protected by AgonGuard.

© 2022-2025 Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.